Efficacy of Oral Semaglutide in Overweight or Obesity (OSO)
Obesity, Weight Loss
About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- Consecutive consenting patients of both genders with either a BMI of 30 or greater or a BMI of 27 or greater with one or more treated or untreated weight-related coexisting conditions (i.e., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
Exclusion Criteria:
• Diabetes mellitus
- A glycated haemoglobin level of 48 mmol per mole (6.5%) or greater,
- A history of chronic pancreatitis
- Acute pancreatitis within 180 days before enrolment
- Previous surgical obesity treatment
- Use of antiobesity medication within 90 days before enrolment
- Pregnancy and planning for pregnancy
- Known malignancy
Sites / Locations
- Asian Institute of Gastroenterology hospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Diet+excercise+oral semaglutide
Diet+excercise
Participants will receive individual counselling sessions for reduced-calorie diet and physical activity (with 150 minutes per week of physical activity, such as walking). Participants in this group will receive oral Semaglutide drug along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on your symptoms (nausea, vomiting, constipation etc)
Participants in this group will receive individual counselling sessions for reduced-calorie diet and increased physical activity (with 150 minutes per week of physical activity, such as walking).